BioNTech Results Presentation Deck

Omicron-BA.1 Adapted Vaccines as 4th Dose Elicit Improved Omicron Neutralization Response FFRNT 50 10,000 1,000 100 10 Participants WITHOUT evidence of infection up to 1 month after first study vaccination >55 yrs old participants, 30 and 60 µg dose 501.1 78.4 OMI 30 µg n=17 822.0 145.3 OMI 60 µg n=18 BA.1 BA.4/5 Internal data. FFRNT, fluorescent foci reduction neutralization test; LOD, limit of detection. GMR, geometric mean ratio 1 GMR superiority criterion: the lower bound of 95% confidence interval for GMR is >1.0 13 2 Non-inferiority criterion: the lower bound of 95% confidence interval for interval for the percentage difference is >-5 3 GMR "super" superiority criterion: the lower bound of 95% confidence interval for GMR is >1.5 771.3 226.3 Bivalent 30 µg n=13 678.1 137.2 Bivalent 60 µg n=18 LOD Superiority¹ for GMR and non-inferiority2 for sero responses (monovalent and bivalent vaccines) "Super" superiority³ for GMR (monovalent vaccines); Neutralization activity against BA.4/5 reduced BIONTECH

View entire presentation